ArdelyxNASDAQ: ARDX

MONSEY, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx”) has violated the federal securities laws after the company announced that it had decided not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment (TDAPA).

Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, currently taking place in Nashville, Tennessee.

Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10.

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company's board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company's common stock, and granted 13 new non-executive employees an aggregate of 179,050 Restricted Stock Units (RSUs). Each stock option has an exercise price equal to $7.44 per share, which was the closing trading price of the company's common stock on the date of grant. The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.

Penny stocks, which are stocks priced under $5, are often considered some of the riskiest investments in the market. Due to their low valuations, many investors choose to steer clear of them.

WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, shared new positive clinical data on XPHOZAH® (tenapanor) at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings in Long Beach, California. Ardelyx is also leading a discussion on managing hyperphosphatemia at the conference.

Ardelyx, Inc. (NASDAQ: ARDX) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET featured Company Representatives Caitlin Lowie, Mike Raab, Susan Rodriguez, and Justin Renz. Various analysts also participated in the conference call. The event was hosted by the operator.